Why "Starting at $99" Does Not Always Mean $99 Per Month
The phrase 'starting at $X/mo' is the most common pricing pattern in GLP-1 telehealth advertising. It rarely represents what patients actually pay over a year of treatment.
GLP-1 Price WatchJune 1, 2026Editorial
Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
'Starting at $99' typically means one of four things:
Lowest-dose first month only. The $99 is the price at starter dose (0.25 mg for sema or 2.5 mg for tirz). Dose-tiered providers raise pricing at each titration step.
Longest prepaid plan only. The $99 is the per-month rate when paying a full year upfront. Shorter terms cost significantly more per month.
Membership only (medication separate). The $99 is membership/program. Medication is a separate line item.
Promotional teaser. The $99 applies for an introductory window (3-12 weeks) and then rises to standard rate.
The pattern is legal — providers disclose the actual pricing structure somewhere. Whether it's misleading depends on prominence and context.
How to Decode Any 'Starting at $X' Claim
Ask the provider directly:
What is the maintenance-dose monthly price?
Does my rate change with my dose?
Is there a separate membership fee?
Are provider visits, labs, and shipping included?
What are the cancellation terms if I want to leave?
No — disclosing a starting price is legal as long as the pricing structure is disclosed somewhere. Whether it's misleading depends on prominence.
Why do providers use teaser pricing?
Lower headline rates win Google Ads bid efficiency, reduce friction for patient acquisition, and let dose-tiered providers earn lifetime customer value while advertising entry rates.
Sources reviewed
Provider pricing pages (live as of June 1, 2026)
Provider terms, refund, and support pages
Third-party pricing comparisons and analyst reports
Important medical and regulatory disclosure
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.